Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Beam Therapeutics (BEAM) Leverages New Financing And IP Control Is Its Gene-Editing Edge Strengthening?
Beam Therapeutics (BEAM) recently reported a significant financial swing to a Q4 2025 net income of US$244.3 million and secured a non-dilutive credit facility of up to US$500 million with Sixth Street, extending its cash runway to mid-2029. The company also reinforced its intellectual property control over core base-editing technology through a direct license with Kobe University, enhancing its platform’s security. These strategic maneuvers aim to strengthen Beam’s financial stability and proprietary technology position as it advances its gene-editing sickle cell candidate towards potential launch.